VRNA vs. ABCL, MNKD, COLL, MIRM, ELVN, PCRX, SYRE, BLTE, PRTA, and GYRE
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include AbCellera Biologics (ABCL), MannKind (MNKD), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Enliven Therapeutics (ELVN), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Belite Bio (BLTE), Prothena (PRTA), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical preparations" industry.
AbCellera Biologics (NASDAQ:ABCL) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
AbCellera Biologics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.
Verona Pharma has a net margin of 0.00% compared to Verona Pharma's net margin of -384.99%. Verona Pharma's return on equity of -12.36% beat AbCellera Biologics' return on equity.
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by insiders. Comparatively, 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Verona Pharma has lower revenue, but higher earnings than AbCellera Biologics. Verona Pharma is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Verona Pharma received 259 more outperform votes than AbCellera Biologics when rated by MarketBeat users. Likewise, 79.90% of users gave Verona Pharma an outperform vote while only 77.27% of users gave AbCellera Biologics an outperform vote.
AbCellera Biologics presently has a consensus target price of $16.17, suggesting a potential upside of 322.11%. Verona Pharma has a consensus target price of $33.60, suggesting a potential upside of 126.26%. Given Verona Pharma's higher probable upside, research analysts plainly believe AbCellera Biologics is more favorable than Verona Pharma.
In the previous week, AbCellera Biologics had 9 more articles in the media than Verona Pharma. MarketBeat recorded 20 mentions for AbCellera Biologics and 11 mentions for Verona Pharma. AbCellera Biologics' average media sentiment score of 0.33 beat Verona Pharma's score of 0.02 indicating that Verona Pharma is being referred to more favorably in the news media.
Summary
AbCellera Biologics beats Verona Pharma on 9 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
